Trials / Conditions / Borderline Resectable Pancreatic Adenocarcinoma

Borderline Resectable Pancreatic Adenocarcinoma

20 registered clinical trials studyying Borderline Resectable Pancreatic Adenocarcinoma — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation NCT07240766	Zhejiang University	Phase 2
Not Yet Recruiting	IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer NCT07415525	Zhejiang University	Phase 2
Recruiting	A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer NCT07080021	Ruijin Hospital	—
Recruiting	PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017	PanTher Therapeutics	Phase 1
Recruiting	Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) NCT06384560	Amsterdam UMC, location VUmc	Phase 1 / Phase 2
Recruiting	Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT05825066	Wake Forest University Health Sciences	Phase 2
Active Not Recruiting	New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancrea NCT04481204	M.D. Anderson Cancer Center	Phase 2
Recruiting	Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adeno NCT05083247	Erasme University Hospital	Phase 2
Recruiting	Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline NCT05688215	Jonsson Comprehensive Cancer Center	Phase 1 / Phase 2
Terminated	A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer NCT05546411	Kimberly Perez, MD	Phase 2
Recruiting	Survival, Quality of Life and Resectability in Locally Advanced Pancreatic Cancer NCT05356039	Umeå University	—
Active Not Recruiting	Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borde NCT04940286	M.D. Anderson Cancer Center	Phase 2
Unknown	Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma NCT04915417	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Active Not Recruiting	Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancr NCT04669197	HonorHealth Research Institute	Phase 2
Suspended	NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreati NCT04484909	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable NCT04106856	University of Utah	Phase 1
Completed	Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancrea NCT03970252	Jonsson Comprehensive Cancer Center	EARLY_Phase 1
Active Not Recruiting	Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2) NCT04423731	Oslo University Hospital	—
Completed	Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With NCT02394535	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarc NCT02446093	Candel Therapeutics, Inc.	Phase 2